Benitec Biopharma to Participate in Upcoming Conferences in January and February
Benitec Biopharma (NASDAQ: BNTC), a clinical-stage biotechnology company specializing in gene therapy and novel genetic medicines based on their proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform, has announced their participation in three upcoming conferences.
The company will attend the Muscular Dystrophy Association Gene Therapy Summit in Tucson, AZ from January 28-30, 2025, followed by the Guggenheim SMID Cap Biotech Conference in New York, NY on February 5, 2025, which will feature one-on-one meetings. Additionally, Benitec will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025, at 2:00 PM EST, offering both a presentation and one-on-one meeting opportunities. The Oppenheimer presentation will be available via live webcast.
Benitec Biopharma (NASDAQ: BNTC), un'azienda biofarmaceutica in fase clinica specializzata in terapia genica e nuovi farmaci genetici basati sulla loro piattaforma proprietaria di interferenza RNA a DNA diretta 'Silence and Replace' (ddRNAi), ha annunciato la propria partecipazione a tre prossime conferenze.
L'azienda parteciperà al Muscular Dystrophy Association Gene Therapy Summit a Tucson, AZ, dal 28 al 30 gennaio 2025, seguito dalla Guggenheim SMID Cap Biotech Conference a New York, NY, il 5 febbraio 2025, che includerà incontri individuali. Inoltre, Benitec presenterà alla virtuale Oppenheimer 35th Annual Healthcare Life Sciences Conference il 12 febbraio 2025, alle 14:00 EST, offrendo sia una presentazione che opportunità di incontri individuali. La presentazione di Oppenheimer sarà disponibile tramite webcast in diretta.
Benitec Biopharma (NASDAQ: BNTC), una empresa de biotecnología en etapa clínica especializada en terapia génica y nuevos medicamentos généticos basados en su plataforma propietaria de interferencia de ARN dirigida por ADN 'Silence and Replace' (ddRNAi), ha anunciado su participación en tres próximas conferencias.
La empresa asistirá a la Muscular Dystrophy Association Gene Therapy Summit en Tucson, AZ, del 28 al 30 de enero de 2025, seguida de la Guggenheim SMID Cap Biotech Conference en Nueva York, NY, el 5 de febrero de 2025, que contará con reuniones individuales. Además, Benitec presentará en la Oppenheimer 35th Annual Healthcare Life Sciences Conference virtual el 12 de febrero de 2025, a las 2:00 PM EST, ofreciendo tanto una presentación como oportunidades para reuniones uno a uno. La presentación de Oppenheimer estará disponible a través de transmisión web en vivo.
Benitec Biopharma (NASDAQ: BNTC)는 유전자 치료 및 그들의 독창적인 'Silence and Replace' DNA 지시 RNA 간섭(ddRNAi) 플랫폼을 기반으로 한 새로운 유전자 의약품을 전문으로 하는 임상 단계의 생명공학 회사로, 세 가지 다가오는 컨퍼런스에 참가한다고 발표했습니다.
회사는 2025년 1월 28일부터 30일까지 애리조나 주 투손에서 열리는 근육 위축 협회 유전자 치료 정상 회담에 참석하고, 이어서 2025년 2월 5일 뉴욕에서 열리는 Guggenheim SMID Cap Biotech Conference에 참석하여 개인 회의가 진행될 예정입니다. 또한, Benitec는 2025년 2월 12일 오후 2시 EST에 열리는 가상 Oppenheimer 제35회 연례 헬스케어 생명과학 회의에서 발표할 예정이며, 발표와 개인 회의 기회를 모두 제공할 것입니다. Oppenheimer 발표는 실시간 웹캐스트를 통해 제공될 예정입니다.
Benitec Biopharma (NASDAQ: BNTC), une entreprise de biopharmacie en phase clinique spécialisée dans la thérapie génique et de nouveaux médicaments génétiques basés sur leur plateforme propriétaire d'interférence ARN dirigée par ADN 'Silence and Replace' (ddRNAi), a annoncé sa participation à trois conférences à venir.
L'entreprise participera au Muscular Dystrophy Association Gene Therapy Summit à Tucson, AZ, du 28 au 30 janvier 2025, suivi par le Guggenheim SMID Cap Biotech Conference à New York, NY, le 5 février 2025, qui comportera des réunions en tête-à-tête. De plus, Benitec présentera lors de la Oppenheimer 35th Annual Healthcare Life Sciences Conference virtuelle le 12 février 2025, à 14h00 EST, offrant à la fois une présentation et des opportunités de réunions en tête-à-tête. La présentation d'Oppenheimer sera disponible via un webcast en direct.
Benitec Biopharma (NASDAQ: BNTC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Gentherapie und neuartige genetische Arzneimittel spezialisiert hat und auf seiner proprietären 'Silence and Replace' DNA-gesteuerten RNA-Interferenz (ddRNAi) Plattform basiert, hat seine Teilnahme an drei bevorstehenden Konferenzen angekündigt.
Das Unternehmen wird vom 28. bis 30. Januar 2025 am Muscular Dystrophy Association Gene Therapy Summit in Tucson, AZ, teilnehmen, gefolgt von der Guggenheim SMID Cap Biotech Conference in New York, NY, am 5. Februar 2025, die Einzelgespräche ermöglichen wird. Darüber hinaus wird Benitec am 12. Februar 2025 um 14:00 Uhr EST bei der virtuellen Oppenheimer 35th Annual Healthcare Life Sciences Conference präsentieren und sowohl eine Präsentation als auch Möglichkeiten für Einzelgespräche anbieten. Die Oppenheimer-Präsentation wird über einen Live-Webcast verfügbar sein.
- None.
- None.
HAYWARD, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences.
Muscular Dystrophy Association Gene Therapy Summit
Dates: January 28 – 30, 2025
Location: Tucson, AZ
Guggenheim SMID Cap Biotech Conference
Date: February 5, 2025
Location: New York, NY
Format: 1x1 Meetings
Oppenheimer 35th Annual Healthcare Life Sciences Conference (being held virtually)
Date: February 12, 2025
Time of Presentation: 2:00 PM EST
Format: Presentation & 1x1 Meetings
The Benitec presentation will also be available via live webcast here.
Please contact your conference representative to schedule a 1x1 meeting with Benitec management.
About Benitec Biopharma Inc.
Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at www.benitec.com.
Investor Relations Contact:
Irina Koffler
LifeSci Advisors
Tel: (917) 734-7387
ikoffler@lifesciadvisors.com
FAQ
What conferences will Benitec Biopharma (BNTC) attend in early 2025?
When is Benitec Biopharma's (BNTC) presentation at the Oppenheimer Healthcare Conference?
Will Benitec's (BNTC) Oppenheimer conference presentation be available online?
What types of meeting formats are available at the conferences BNTC is attending?
What is the technology platform that Benitec (BNTC) is developing?
